|February 19, 2020
|Elucidating Aberrant Splicing-Induced Immune Pathway Activation in RBMl0-Deficient KRAS-Mutant NSCLC and Harnessing Its Potential for Precision Immunotherapy
|The University of Texas M.D. Anderson Cancer Center
|Principal Investigator/Program Director
|Lung and Bronchus
Despite significant progress in the past decade non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality world-wide. Particularly challenging among NSCLC patients are those whose tumors harbor mutations in KRAS (~30% of lung adenocarcinomas), that account for ~25,000 deaths annually in the US. Since 2015, immunotherapy (IO) with PD-1/PD-L1 inhibitors has transformed NSCLC clinical practice; however only ~ 25% of KRAS-mutant NSCLC respond to PD-1/PD-L1 inhibitors. Improved understanding of the immunobiology of KRAS-mutant NSCLC and development of novel immunotherapeutic strategies are critical in order to improve clinical outcomes. We previously identified that...